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Abstract The effect of several aminoglycoside antibiotics on
ribonuclease P (RNase P) was investigated using an in vitro
experimental system from Dictyostelium discoideum. Detailed
kinetic analysis showed that all aminoglycosides tested (tobra-
mycin, gentamicin, kanamycin, paromomycin, neomycin) behave
as classical non-competitive inhibitors, with neomycin being the
strongest inhibitor. The inhibition effect is attributed to the
electrostatic competition of the cationic aminoglycosides with
magnesium ions required for catalysis. Increasing Mg2+ ion
concentrations reduced the effect of aminoglycosides on RNase P
activity. Detailed kinetic analysis showed that aminoglycosides
compete with Mg2+ for common binding sites on RNase P
holoenzyme. ß 2000 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Antibiotics are produced by microorganisms as products of
secondary metabolism, possessing the ability to kill or inhibit
the growth of bacteria and other microorganisms. The discov-
ery of the catalytic properties of RNA has brought RNA-
binding antibiotics to proscenium. Most of them have riboso-
mal RNA as a target [1,2]. Also, many pathogen-speci¢c
RNAs, such as those of human hepatitis delta virus (HDV)
and human immunode¢ciency virus (HIV), are inhibited by
certain antibiotics [3]. Inhibition of RNA biological activity
can occur in various ways; by preventing binding of another
macromolecule (protein or RNA), by distorting the RNA ac-
tive conformation, by competitive binding for a cofactor bind-
ing site, or by displacing catalytically important ions, such as
magnesium ions [4]. Aminoglycoside antibiotics are known to
disturb the decoding process [1]. The decoding function of the
ribosome is attributed to the small ribosomal subunit, and
takes place at the ribosomal A-site, a region located near
the 3P end of the 16S rRNA. The aminoglycoside antibiotics
impair the decoding function by acting on this region [2].
These antibiotics, thought to act speci¢cally on the ribosome,
also act as inhibitors of catalytic RNAs, such as the self splic-
ing group I introns [5], the hammerhead ribozyme [6], the
HDV ribozyme [7], the hairpin ribozyme [8], the HIV RNA
[9] or Escherichia coli RNase P RNA [10].
The ribonucleoprotein RNase P is the endonuclease respon-
sible for the maturation of 5P termini of tRNA molecules [11].
Divalent metal ions are essential for e⁄cient chemical catal-
ysis by RNase P. Among them, Mg2 promotes cleavage most
e⁄ciently [12]. Recently, in a study on the metal ion require-
ments of RNase P from Dictyostelium discoideum we showed
that there are two metal ion binding sites, one activating and
another one inhibitory, and we proposed that one Mg2 ion
promotes the cleavage mechanism of D. discoideum RNase P
[13]. In vitro, the RNA subunits of RNase P enzymes from
bacteria [14] and from some archaea [15] are catalytically
active in the absence of protein and are the only known
RNA catalysts naturally devoted to act in trans. Similar be-
havior has not yet been demonstrated for eukaryotic RNase P
enzymes. Although the latter, include an RNA subunit of
similar size as found in their prokaryotic counterparts, they
are composed of multiple protein components which contrib-
ute about 70% to the enzyme’s molar mass [16]. This high
protein/RNA ratio is a common feature of all eukaryotic nu-
clear RNase P enzymes characterized to date [11], including
nuclear D. discoideum RNase P [17]. In addition, human or-
thologues of the yeast RNase P protein subunits have been
found [18]. These ¢ndings indicate that the structures of
RNase P enzymes from di¡erent eukaryotes are similar.
Thus, D. discoideum RNase P is a good model system for
other eukaryotic RNase P enzymes, such as the human nu-
clear RNase P, and could become a promising system to eval-
uate toxic side e¡ects of antimicrobial inhibitors. Recently, we
reported that natural and synthetic retinoids inhibit D. discoi-
deum RNase P activity [19].
In the present study we examined the e¡ect of several ami-
noglycosides on RNase P activity from D. discoideum. The
in£uence of Mg2 on aminoglycoside inhibition e¡ect is also
analyzed, and the molecular basis of this relationship is dis-
cussed.
2. Materials and methods
All chemicals were obtained from commercial sources. Aminoglyco-
sides were obtained from Sigma.
2.1. Assay for RNase P activity
Enzyme assays were carried out at 37‡C in 20 Wl bu¡er D (50 mM
Tris^HCl pH 7.6, 5 mM MgCl2, 10 mM NH4Cl) in the presence of
5 fmol labeled transcript of the Schizosaccharomyces pombe tRNASer
gene supS1 and 1.3 Wg protein from the RNase P fraction, if not
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. Published by Elsevier Science B.V. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 2 1 9 0 - 6
*Corresponding author. Fax: (30)-61-997690.
E-mail: drainas@med.upatras.gr
1 Present address: Department of Molecular Biophysics and Bio-
chemistry, Yale University, 266 Whitney Av., P.O. Box 208114, New
Haven, CT 06520-8114, USA.
FEBS 24293 13-11-00
FEBS 24293 FEBS Letters 485 (2000) 71^75
stated otherwise. The reactions were stopped by addition of 5 Wl stop
dye (80% formamide, 50 mM EDTA, 0.1% bromophenol blue, 0.1%
xylene cyanol). Reaction products were resolved on 10% polyacryl-
amide/8 M urea gels and visualized by autoradiography without dry-
ing. Activity was quanti¢ed by Cerenkov counting of excised gel sli-
ces.
2.2. Enzyme puri¢cation
Growth of D. discoideum cells (strain AX2 wild type), cell breakage
and the production of S-100 fraction were carried out as previously
described [17]. The puri¢cation procedure consisting of two steps of
anion exchange chromatography (DE-52 cellulose) followed by gel
¢ltration as a ¢nal step (Sephacryl S-300) was carried out as previ-
ously described [13].
3. Results
Our present study was designed to evaluate the e¡ect of
several aminoglycosides on RNase P from D. discoideum in
a cell free system. These included tobramycin, gentamicin,
kanamycin, paromomycin and neomycin (Fig. 1). All inhib-
itors tested are capable of inhibiting the RNase P activity of
D. discoideum in a dose response manner (Fig. 2A). The con-
centration of kanamycin, paromomycin, tobramycin, gentami-
cin and neomycin at which the product formation is reduced
by 50% (IC50) is equal to 2.6, 2.2, 1.7, 1.3 and 0.25 mM
respectively. When the Mg2 was increased, a reduced inhibi-
tion of RNase P cleavage by all aminoglycosides was ob-
served. Increasing Mg2 from 1 to 5 mM, at a constant neo-
mycin concentration, resulted in a considerable recovery of
the activity (about 40%) (Fig. 2B). Similar curves where ob-
tained with tobramycin, gentamicin, kanamycin and paromo-
mycin (data not shown). It is obvious that the maximum in-
hibitory e¡ect was achieved when the reaction was carried out
in the presence of 1 mM Mg2. At this concentration, the
activating site of the enzyme is not saturated with Mg2
[13]. It is important to note that the tested antibiotics exhibit
the same e¡ect regardless if the ¢nal S-300 step of RNase P
puri¢cation [13] is included or not.
The inhibition mode of D. discoideum RNase P activity by
aminoglycosides was further investigated by detailed kinetic
analysis in the presence of 1 mM Mg2. Fig. 3A shows double
reciprocal plots with increasing concentration of neomycin
which indicate that the inhibition is of a non-competitive
type. The slopes of the lines in Fig. 3A were plotted against
the concentration of neomycin, and the results are shown in
the top panel of Fig. 3A. The linearity of this plot is indicative
for simple non-competitive inhibition and permits the graph-
ical determination of Ki = 143 WM from the negative intercept
of the line with the I-axis. The same kinetic analysis was
carried out for tobramycin, gentamicin, kanamycin and paro-
momycin. All these compounds showed simple non-competi-
Fig. 1. Structures of aminoglycosides. A: The aminoglycosides neomycin B (R1 = NH2) and paromomycin (R1 = OH). B: The aminoglycosides
gentamicin C1 (R1 = R2 = CH3), gentamicin C3 (R1 = CH3, R2 = H), gentamicin C1a (R1 = R2 = H). C: The aminoglycosides tobramycin
(R1 = NH2, R2 = H) and kanamycin A (R1 = R2 = OH).
Table 1
Equilibrium constants derived from primary and secondary kinetic
plots (see Fig. 3)
Inhibitor Ki (WM)
Neomycin B 143
Gentamicin 734
Tobramycin 1074
Paromomycin 1414
Kanamycin 1871
The Ki values are calculated from the negative intercept of the slope
replots (see Fig. 3, inset).
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tive inhibition. The corresponding Ki values are shown in
Table 1. To evaluate the molecular order of inhibition by
aminoglycosides, we used the equation:
v0
v03v0
 K i 1In
where n represents the Hill coe⁄cient. This equation was de-
rived from the di¡erential rate law:
v0  Vmax S
K s  S 1 I
n
K i
 
which corresponds to the kinetic model:
involving non-competitive inhibitor interacting with an en-
zyme at multiple sites. When n = 1, the plot of vP/(v03vP) ver-
sus 1/[neomycin] is linear. The vP/(v03vP) values were calcu-
lated at each concentration of pre-tRNA and plotted as a
function 1/[neomycin]. Such a plot, based on velocities ob-
tained at substrate concentration of 100 nM, is given in Fig.
3B. The linearity of this plot supports that only one molecule
of neomycin is kinetically involved in the mechanism of inhi-
bition. Very similar plots were obtained for paromomycin,
gentamicin, kanamycin and tobramycin (not shown).
Further kinetic analysis revealed that neomycin competes
with Mg2 for common binding sites on the enzyme. Double
reciprocal plots 1/v versus 1/[Mg2], with increasing concen-
tration of neomycin in the presence of 100 nM precursor
tRNA, indicate that aminoglycosides and Mg2 compete for
the same binding sites of the enzyme (Fig. 4A). Furthermore,
Fig. 2. A: Dose response e¡ects of neomycin (8), paromomycin (F), gentamicin (R), kanamycin (a), and tobramycin (b) on the RNase P
processing reaction. B: Inhibition of the RNase P reaction in the presence of 0.2 mM neomycin and increasing concentrations of Mg2. All
data presented are averaged values of ¢ve individual experiments.
Fig. 3. A: Double reciprocal plot 1/v versus 1/[pre-tRNA] for the
RNase P reaction in the presence of neomycin. The reaction was
carried out at the indicated substrate concentrations in the presence
or in the absence of inhibitor. All reactions were carried out in 20 Wl
bu¡er D with 1 mM MgCl2. (8) Control without inhibitor; with
neomycin at 50 WM (F), 75 WM (R), 100 WM (a), 150 WM (E),
200 WM (b). Inset: Replot of the slopes of the double reciprocal
lines versus inhibitor (I) concentration. B: Variation of vP/(v03vP) as
a function of 1/[I]. The vP and v0 values (at 100 nM substrate con-
centration) were deduced from the double reciprocal plot.
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the linearity of the slope replot is characteristic of simple
competitive interaction (Fig. 4A, inset).
Finally, we investigated the pH dependence on neomycin
inhibition. At higher pH values a considerable reduction in
the inhibition was observed (pH 8.5) (data not shown), sug-
gesting the importance of the presence of protonated amino
groups for the inhibitory e¡ect of neomycin.
4. Discussion
In the present study, it has been revealed that the amino-
glycosides tobramycin, gentamicin, kanamycin, paromomycin
and neomycin exhibit a dose-dependent inhibition e¡ect on
tRNA maturation by eukaryotic nuclear RNase P. These ami-
noglycosides belong to three di¡erent groups; the neomycin
group (Fig. 1A), the gentamicin group (Fig. 1B) which is a
mixture of gentamicin C1, C1a and C3, and the kanamycin
group (Figure 1C). Detailed kinetic analysis showed that the
aminoglycosides behave as classical non-competitive inhibi-
tors. Therefore, the potency of these inhibitors could be as-
signed on the basis of Ki values. Neomycin is 5.13, 7.5, 9.9
and 13.1 times more potent than gentamicin, tobramycin, pa-
romomycin, or kanamycin respectively. The higher potency of
neomycin could be attributed to the high number of amino
groups. Neomycin has six amino groups, paromomycin, gen-
tamicin and tobramycin have ¢ve amino groups and kanamy-
cin has four amino groups (Fig. 1). Taking into account that
neomycin is 9.9U and tobramycin is 1.7U more potent inhib-
itors than paromomycin and kanamycin, respectively (Table
1), it can be concluded that the ammonium group at the R1
position of the aminoglycoside molecule (Fig. 1) is important
in the process of inhibition. Considerably weaker inhibition at
higher pH values indicates that binding of neomycin B to the
enzyme depends on the protonation of its amino group. Since
D. discoideum RNase P is a ribonucleoprotein it is possible
that aminoglycosides bind the polyanionic RNA moiety of the
enzyme through ionic interactions.
Our data indicate that protonated amino groups of amino-
glycosides play a crucial role in the inhibition of cleavage by
the protein-rich RNase P enzyme from D. discoideum. The
inhibition caused by all aminoglycosides tested was sensitive
to Mg2 concentration. When the concentration of Mg2 was
increased from 1 to 5 mM, a 40% recovery of the activity was
observed. Full recovery of the enzyme activity can not be
achieved due to the fact that, above 5 mM, Mg2 binds
also to the inactivating metal ion binding site [13]. In agree-
ment with these data, the maximum inhibitory e¡ect of ami-
noglycosides was observed at 1 mM Mg2, a situation where
the activating site of the enzyme was not saturated with Mg2.
Detailed kinetic analysis showed that Mg2 and aminoglyco-
sides compete for common binding sites. To evaluate the mo-
lecular order of RNase P inhibition by neomycin, the vP/
(v03vP) values were calculated at di¡erent concentrations of
pre-tRNA and replotted as a function of 1/[neomycin]. Such a
plot, obtained at 100 nM pre-tRNA, is given in Fig. 4. The
linearity of this plot indicates that only one molecule of neo-
mycin is kinetically involved in the mechanism of inhibition.
Linear plots were taken for paromomycin, gentamicin, kana-
mycin and tobramycin (not shown). Therefore, we can assume
that aminoglycosides compete with Mg2 ions for one binding
site, the activating site of D. discoideum RNase P [13]. Due to
the fact that the stoichiometry was deduced by a kinetic curve,
rather than from a real measurement of the amount of bound
neomycin, we can not exclude the existence of additional neo-
mycin binding sites on RNase P. Our ¢ndings are in agree-
ment with previously reported data on aminoglycoside inhibi-
tion of HDV [7], hammerhead ribozyme [20,21], self splicing
group I intron [22] and E. coli RNase P [10]. It has been
suggested by these studies that aminoglycoside antibiotics
achieve inhibition of ribozyme cleavage by replacement of
structurally important magnesium ions with protonated ami-
no groups.
The e¡ect of tobramycin, gentamicin, kanamycin, paromo-
mycin and neomycin on RNase P activity indicates that these
compounds, in addition to their inhibitory e¡ect on protein
synthesis, exert a direct e¡ect on tRNA biogenesis. It is be-
coming evident that RNase P is a valuable experimental sys-
tem for the in vitro study of the biological activity of anti-
biotics, which may provide a much more di¡erentiated picture
of the molecular basis of antibiotic action. D. discoideum
RNase P seems to be an excellent eukaryotic model system
for the study of complex, relatively protein-rich ribonucleo-
protein particles, a category of macromolecular complexes to
which the eukaryotic ribosome, RNase MRP, the SRP par-
ticle and snRNP particles belong. Studies on D. discoideum
RNase P allow to evaluate toxic side e¡ects of potential anti-
microbial inhibitors in eukaryotic organisms.
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Fig. 4. Double reciprocal plot 1/v versus 1/[Mg2] for the RNase P
reaction in the presence or in the absence of neomycin. (F) Control
without neomycin; with neomycin at (a) 50 WM, (b) 100 WM, (R)
150 WM. Inset: Replot of the slopes of the double reciprocal lines
versus inhibitor (I) concentration.
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